Omeros Corporation (OMER)
Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us
Omeros Corporation's stock rebounded after successful data analysis for narsoplimab, showing 68% lower death risk in HSCT-TMA patients compared to historical controls. FDA requested new statistical analysis for narsoplimab's BLA resubmission, which proved successful, leading to a potential approval by late 2025. Financial risks include limited cash runway and potential market constraints due to upcoming generic competition and insurance issues.
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges
On Thursday, Omeros Corporation OMER announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab.
Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Jennifer Cook Williams - Investor and Media relations, Cook Williams Communications, Inc. Gregory Demopulos - Chairman and Chief Executive Officer David Borges - Chief Accounting Officer Andreas Grauer - Chief Medical Officer Steven Whitaker - Vice President, Clinical Development Conference Call Participants Steve Brozak - WBB Olivia Brayer - Cantor Fitzgerald Serge Belanger - Needham & Company Operator Good afternoon, and welcome to today's conference call for Omeros Corporation. At this time, all participants are in a listen-only mode.
Omeros Corporation (OMER) Q2 2024 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER ) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Jennifer Cook Williams - Investor Relations, Cook Williams Communications, Inc. Gregory Demopulos - Chairman and Chief Executive Officer David Borges - Chief Accounting Officer Catherine Melfi - Chief Regulatory Officer Nadia Dac - Chief Commercial Officer Andreas Grauer - Chief Medical Officer Steven Whitaker - Vice President-Clinical Development Conference Call Participants Steve Brozak - WBB Securities Olivia Brayer - Cantor Fitzgerald John Gionco - Needham & Company Operator Good afternoon and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode.
